Clinical Precise Diagnosis and Treatment in the Kawasaki Disease

Study Overview
=================
Brief Summary
-----------------
The purpose of this project is to explore the differential gene expression profile of Kawasaki disease, and will explore the diagnosis and treatment targets related to coronary artery injury or kawasaki disease susceptibility, vascular damage, IVIG (intravenous immunoglobulin) treatment resistance, incomplete Kawasaki disease, etc.

Detailed Description
-----------------
After being informed about the study and potential risks, all patients giving written informed consent will acquire blood samples with complete clinical data and prognostic information. Using clinicopathology, molecular biology, gene diagnostics and other techniques to verify the expression differences of target genes and proteins and analyze their expression levels; To analyze the role of target genes and proteins in the occurrence and development of Kawasaki disease and their correlation with the risk of coronary artery injury. In vitro and in vivo KD (Kawasaki Disease) model was used to investigate the role of target genes in Kawasaki disease by gene interference and various molecular biological techniques.

Official Title
-----------------
Clinical Precise Diagnosis and Treatment of Personalized Z-score Evaluation Combined With Genomic Analysis in the Repair of Coronary Artery Injury in Kawasaki Disease

Conditions
-----------------
Kawasaki Disease

Intervention / Treatment
-----------------
* Diagnostic Test: Echocardiography, Genomics NGS sequencing


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Individual patient's medical file data confirmed the diagnosis of KD using diagnostic criteria issued by the American Heart Association in 2017; Patients were respond to IVIG treatment; the patients aged from 2 months to 14 years old; All included patients required to sign an informed consent form. Exclusion Criteria: The patients with severe infections; The patients with a history of tuberculosis or recent close contact with tuberculosis; The patient vaccinated with live vaccine in 6 months; The patients with the application of hormone or other immunosuppressive agents; The patients didnt want to signed informed consent.

Ages Eligible for Study
-----------------
Minimum Age: 1 Month
Maximum Age: 14 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Health Control<br>Health children with age and sex paired with experimental group | Diagnostic Test: Echocardiography, Genomics NGS sequencing<br>* The inner diameter of left main coronary artery, anterior descending branch, circumflex branch and right coronary artery was measured by echocardiography. Blood samples were send for genomics NGS sequencing<br>|
| Kawasaki Disease<br>KD patients, with no congenital heart disease, metabolic disease or Immune deficiency disease. | Diagnostic Test: Echocardiography, Genomics NGS sequencing<br>* The inner diameter of left main coronary artery, anterior descending branch, circumflex branch and right coronary artery was measured by echocardiography. Blood samples were send for genomics NGS sequencing<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Z-score of coronary artery | Calculate z-score by using LMS regression form echocardiography data | 2 weeks | 
| Z-score of coronary artery | Calculate z-score by using LMS regression form echocardiography data | 4 weeks | 
| Differential gene profile | Differential expression analysis of NGS sequencing in genomics | 0 week | 
| Differential gene profile | Differential expression analysis of NGS sequencing in genomics | 1 week after IVIG treatment |